ADA Scientific Sessions 2025 Abstract

Impact of ReCET Therapy on Continuous Glucose Monitoring (CGM) Metrics in Type 2 Diabetes—Insights from the REGENT-1 Trial

By David N. O'Neal, John Apostolopoulos, Adrian Sartoretto, Elif Ilhan Ekinci

Trial in peopleInterventions

The paper

David N. O'Neal, John Apostolopoulos, Adrian Sartoretto, Elif Ilhan Ekinci

Fitzroy

ADA Scientific Sessions 2025 Abstract, 13 Jun 2025

Presented at ADA Scientific Sessions 2025, poster 892-P

doi.org/10.2337/db25-892-p

Lancet4 Oct 2026
Retatrutide reduces bodyweight in obesity and type 2 diabetes
The New England Journal of Medicine4 Oct 2026
Survodutide reduces weight in adults with diabetes and obesity
Cell Metabolism8 Oct 2026
A triple-target drug cut body weight by up to 19.7% in a trial